Flavian D Brown
Overview
Explore the profile of Flavian D Brown including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
2777
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brown F, Sen D, LaFleur M, Godec J, Lukacs-Kornek V, Schildberg F, et al.
Nat Immunol
. 2019 Oct;
20(12):1668-1680.
PMID: 31636464
Lymph node fibroblastic reticular cells (FRCs) respond to signals from activated T cells by releasing nitric oxide, which inhibits T cell proliferation and restricts the size of the expanding T...
2.
Miller B, Sen D, Al Abosy R, Bi K, Virkud Y, LaFleur M, et al.
Nat Immunol
. 2019 Oct;
20(11):1556.
PMID: 31582823
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
3.
LaFleur M, Nguyen T, Coxe M, Yates K, Trombley J, Weiss S, et al.
Nat Commun
. 2019 Apr;
10(1):1668.
PMID: 30971695
Therapies that target the function of immune cells have significant clinical efficacy in diseases such as cancer and autoimmunity. Although functional genomics has accelerated therapeutic target discovery in cancer, its...
4.
Miller B, Sen D, Al Abosy R, Bi K, Virkud Y, LaFleur M, et al.
Nat Immunol
. 2019 Feb;
20(3):326-336.
PMID: 30778252
T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates...
5.
Ishizuka J, Manguso R, Cheruiyot C, Bi K, Panda A, Iracheta-Vellve A, et al.
Nature
. 2018 Dec;
565(7737):43-48.
PMID: 30559380
Most patients with cancer either do not respond to immune checkpoint blockade or develop resistance to it, often because of acquired mutations that impair antigen presentation. Here we show that...
6.
Manguso R, Pope H, Zimmer M, Brown F, Yates K, Miller B, et al.
Nature
. 2017 Jul;
547(7664):413-418.
PMID: 28723893
Immunotherapy with PD-1 checkpoint blockade is effective in only a minority of patients with cancer, suggesting that additional treatment strategies are needed. Here we use a pooled in vivo genetic...
7.
Sen D, Kaminski J, Barnitz R, Kurachi M, Gerdemann U, Yates K, et al.
Science
. 2016 Oct;
354(6316):1165-1169.
PMID: 27789799
Exhausted T cells in cancer and chronic viral infection express distinctive patterns of genes, including sustained expression of programmed cell death protein 1 (PD-1). However, the regulation of gene expression...
8.
Kim H, Barnitz R, Kreslavsky T, Brown F, Moffett H, Lemieux M, et al.
Science
. 2015 Oct;
350(6258):334-9.
PMID: 26472910
The maintenance of immune homeostasis requires regulatory T cells (T(regs)). Given their intrinsic self-reactivity, T(regs) must stably maintain a suppressive phenotype to avoid autoimmunity. We report that impaired expression of...
9.
Brown F, Turley S
J Immunol
. 2015 Feb;
194(4):1389-94.
PMID: 25663676
The connective tissue of any organ in the body is generally referred to as stroma. This complex network is commonly composed of leukocytes, extracellular matrix components, mesenchymal cells, and a...
10.
Fletcher A, Elman J, Astarita J, Murray R, Saeidi N, DRozario J, et al.
Sci Transl Med
. 2014 Aug;
6(249):249ra109.
PMID: 25122637
Sepsis is an aggressive inflammatory syndrome and a global health burden estimated to kill 7.3 million people annually. Single-target molecular therapies have not addressed the multiple disease pathways triggered by...